000153 Anhui Fengyuan Pharmaceutical
- 8.24
- -0.03-0.36%
Anhui Fengyuan Pharmaceutical News
As of May 31, 2024, the number of shareholders of Anhui Fengyuan Pharmaceutical (000153.SZ) was 38,682.
Anhui Fengyuan Pharmaceutical (000153.SZ) stated on the investor interaction platform that as of May 31, 2024, the number of shareholders in the company was 38682.
There's A Lot To Like About Anhui Fengyuan Pharmaceutical's (SZSE:000153) Upcoming CN¥0.15 Dividend
Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE:000153) is about to trade ex-dividend in the next three days. The ex-dividend date is usually set to be one business day before the record date which is
Fengyuan Pharmaceutical (000153.SZ): 2023 equity distribution of 10 to 4 transfers of 1.5 yuan share registration date June 6
Gelonghui, May 29丨Fengyuan Pharmaceutical (000153.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 1.5 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 332,026,230 shares. At the same time, the capital reserve fund will be used to transfer 4 shares for every 10 shares to all shareholders. The share registration date for this equity distribution is June 6, 2024, and the ex-dividend date is June 7, 2024.
Fengyuan Pharma Gets Nod to Register Two Dialysis Solutions
Chinese drug regulator National Medical Products Administration granted drug registration certificates to two of Anhui Fengyuan Pharmaceutical's (SHE:000153) dialysis solutions, the company said in it
Fengyuan Pharmaceutical (000153.SZ) obtained two drug registration certificates
Fengyuan Pharmaceutical (000153.SZ) announced that the company received approval from the State Drug Administration for low calcium peritoneal penetration...
Fengyuan Pharmaceutical (000153.SZ): Low calcium peritoneal dialysis solution (lactate-G 1.5%) and low calcium peritoneal dialysis solution (lactate-G 2.5%) obtained drug registration certificates
Gelonghui, May 10, 丨 Fengyuan Pharmaceutical (000153.SZ) announced that recently, the company received the “Drug Registration Certificate” (certificate number: 2024S00742) for the low-calcium peritoneal dialysate (lactate-G 2.5%) and the “Drug Registration Certificate” (certificate number: 2024S00741) and low-calcium peritoneal dialysis solution (lactate-G 1.5%) approved and issued by the State Drug Administration.
Fengyuan Pharmaceutical (000153.SZ): The company currently has no traditional Chinese medicine cultivation base
Gelonghui May 9 丨 Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that the company currently has no traditional Chinese medicine cultivation base.
Anhui Fengyuan Pharmaceutical's (SZSE:000153) Problems Go Beyond Weak Profit
Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) stock showed strength, with investors undeterred by its weak earnings report. While shareholders may be willing to overlook soft profit numbers
Fengyuan Pharmaceutical (000153.SZ): Net profit of 47.0109 million yuan in the first quarter increased 2.14% year over year
On April 25, Ge Longhui Pharmaceutical (000153.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,121 billion yuan, down 7.08% year on year; net profit attributable to shareholders of listed companies was 47.0109 million yuan, up 2.14% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.6746 million yuan, up 4.96% year on year; basic earnings per share were 0.1,416 yuan.
Fengyuan Pharmaceutical (000153.SZ): The subsidiary Maanshan Fengyuan Pharmaceutical currently produces and operates normally
Gelonghui, April 22丨Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that Maanshan Fengyuan Pharmaceutical, a subsidiary of the company, currently produces and operates normally. The drug GMP compliance inspection is a compliance inspection applied for by Maanshan Fengyuan Pharmaceutical after increasing equipment through technical modifications due to insufficient production capacity in the atticaine production line; after the initial inspection did not pass, Maanshan Fengyuan Pharmaceutical re-formulated a plan for the inspection results and has now applied for a drug GMP compliance test again; after the compliance inspection is passed, the production capacity of Maanshan Fengyuan Pharmaceutical's atticaine products will be greatly increased.
Fengyuan Pharmaceutical (000153.SZ) received two drug registration certificates
According to the Zhitong Finance App, Fengyuan Pharmaceutical (000153.SZ) issued an announcement. The company received the approval and issuance of peritoneal dialysis solution (lactate-G 2.5%), “Drug Registration Certificate” (certificate number: 2024S00438) and peritoneal dialysis solution (lactate-G 1.5%) and “Drug Registration Certificate” (certificate number: 2024S00439) from the State Drug Administration. The above drugs are suitable for patients with acute and chronic renal failure requiring continuous insular peritoneal dialysis treatment due to ineffectiveness of non-dialysis treatment.
Fengyuan Pharmaceutical (000153.SZ) obtained drug registration certificates for peritoneal dialysis solution (lactate-G 1.5%) and peritoneal dialysate (lactate-G 2.5%)
Gelonghui, March 27丨Fengyuan Pharmaceutical (000153.SZ) announced that recently, the company received the “Drug Registration Certificate” (certificate number: 2024S00438) for peritoneal dialysis solution (lactate-G 2.5%) and peritoneal dialysis solution (lactate-G 1.5%) and “Drug Registration Certificate” (certificate number: 2024S00439) approved and issued by the State Drug Administration. The peritoneal dialysis solution (lactate-G 1.5%) and peritoneal dialysis solution (lactate-G 2.5%), which the company has obtained a drug registration certificate this time, are suitable for abdominals requiring continuous sleepless nights due to ineffectiveness of non-dialysis treatment
Fengyuan Pharmaceutical (000153.SZ): Exports some APIs and other formulations, but sales account for a relatively small share
Gelonghui March 25 丨 Some investors asked Fengyuan Pharmaceutical (000153.SZ) on the investor interactive platform, “What products are exported and how much is the sales revenue”. The company replied that the company exports some APIs and other formulations, but the sales account for a relatively small share.
Fengyuan Pharmaceutical (000153.SZ): As of March 8, 2024, the number of shareholders of the company was 40,437
Gelonghui March 13 | Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that as of March 8, 2024, the number of shareholders of the company was 40,437.
Fengyuan Pharmaceutical (000153.SZ): The subsidiary is not currently producing erythritol products
Gelonghui Feb. 26 | Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that the company's subsidiary is not currently producing erythritol products.
Fengyuan Pharmaceutical (000153.SZ): As of February 20, 2024, the number of shareholders of the company was 40,220
Gelonghui February 22丨Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 40,220.
Little Excitement Around Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Earnings As Shares Take 26% Pounding
The Anhui Fengyuan Pharmaceutical Co., Ltd. (SZSE:000153) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has capped off a tough
Fengyuan Pharmaceutical (000153.SZ) plans to spend 350 million yuan to build a pharmaceutical formulation project
Fengyuan Pharmaceutical (000153.SZ) announced that Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (hereinafter referred to as “...
Fengyuan Pharmaceutical (000153.SZ): As of January 20, 2024, the number of shareholders of the company was 39,885
Gelonghui January 26 | Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that as of January 20, 2024, the number of shareholders of the company was 39,885.
Fengyuan Pharmaceutical (000153.SZ): As of January 10, 2024, the number of shareholders of the company was 39,729
Gelonghui January 12 | Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 39,729.
Analysis
Price Target
No Data
